Psychotropic Medication Usage in Individuals with Fetal Alcohol Spectrum Disorders (FASD) and Psychiatric Co-morbidities in Canada
Main Article Content
Background and objective
Individuals with Fetal Alcohol Spectrum Disorder (FASD) tend to be prescribed a high number of psychotropic medications to treat high rates of comorbid psychiatric disorders. A lack of guidance regarding best practices for prescribing psychotropic medications to individuals with FASD probably accounts for this reliance on polypharmacy. The objective of this study is to describe the types of medications prescribed to individuals with prenatal alcohol exposure, comparing rates between individuals diagnosed with FASD and individuals without FASD as well as how medications are prescribed based on age, sex, and comorbid psychiatric disorders.
Material and methods
Data were drawn from Canada’s national FASD database. This database includes information collected during an FASD assessment related to diagnostic outcomes, secondary challenges, and medical and mental health information. Descriptive statistics were calculated for four diagnostic groups (FASD with sentinel facial features [FASD + SFF], FASD without sentinel facial features [FASD - SFF], at risk for FASD [“at risk”], and no FASD). Group demographics were compared using Chi-Square, Fisher’s Exact Test, and ANOVA, as appropriate. Differences in the proportion of individuals between these four diagnostic groups were calculated using each of the following six classes of psychotropic medications—antipsychotics, antidepressants/anxiolytic, anticonvulsants/mood stabilizers, stimulants, melatonin, and others—using ANOVA. Considering just the individuals with FASD by combining the FASD + SFF and FASD - SFF groups, independent sample tests were used to compare differences in the proportion of males and females prescribed different medications. Chi-Square and Fisher’s Exact Test were used to compare the proportion of individuals using psychotropic medications, according to category, within the FASD group based on the presence or absence of 13 comorbid psychiatric disorders.
The overall sample included 2349 participants (mean value = 18.1 years, SD = 10.3). The sample included 1453 participants with an FASD diagnosis (n = 218, FASD + SFF, mean = 23.7 years, SD = 15.8, and n = 1235, FASD - SFF, mean = 19.5 years, SD = 10.0 years) and 896 participants who were assessed but did not receive an FASD diagnosis (n = 653, no FASD, mean = 16.1 years and n = 261, “at risk” for FASD, mean = 12.2 years). The FASD groups had a significantly higher rates of anxiety disorders, depressive disorders, and the presence of at least one comorbid psychiatric disorder compared to the no FASD and the “at risk” groups. Both FASD groups had a higher proportion of individuals taking antipsychotic and antidepressant/anxiolytic medications compared to the no FASD and “at risk” groups. Females with FASD were more often prescribed antidepressants/anxiolytics compared to males with FASD, while males with FASD were more often prescribed stimulants than females with FASD. The prevalence of antidepressants/anxiolytics, stimulants, and melatonin use by individuals with FASD differed across the lifespan. The prevalence of the prescription of six medication categories was found to differ according to psychiatric disorder.
Compared to individuals assessed as not fulfilling criteria for FASD, those with FASD had higher rates of psychiatric disorders and were prescribed significantly more antidepressants/anxiolytics and antipsychotics. The class and rate of prescriptions may support efforts in devising treatment guidelines for a complex disorder with known high comorbidity such as FASD.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of articles published in all DPG titles is retained by the author(s). The author(s) grants DPG the rights to publish the article and identify itself as the original publisher. The author grants DPG exclusive commercial rights to the article. The author grants any party the rights to use the article freely for non-commercial purposes provided that the original work is properly cited.
2. Harding KD, Wrath AJ, Flannigan K, Unsworth K, McFarlane A, Pei J. Fetal alcohol spectrum disorder: The importance of adopting a standard definition in Canada. J Fetal Alcohol Spect Disord. 2022; 4(SP1): e5-e19. https://doi.org/10.22374/jfasd.v4iSP1.10
3. Flannigan K, Unsworth K, Harding K. The prevalence of Fetal Alcohol Spectrum Disorder. Canada FASD Research Network. Vancouver, BC, Canada: CanFASD; 2018.
4. Rasmussen C, Andrew G, Zwaigenbaum L, et al. Neurobehavioural outcomes of children with fetal alcohol spectrum disorders: A Canadian perspective. Paediatr Child Health. 2008;13(3):185.
5. Himmelreich M, Lutke C, Hargrove E. The lay of the land: Fetal Alcohol Spectrum Disorder (FASD) as a whole-body diagnosis. In: Begun AL, Murray MM, editors. The Routledge handbook of social work and addictive behaviors. London: Taylor and Francis; 2020. pp. xxx. https://doi.org/10.4324/9780429203121-14
6. Weyrauch D, Schwartz M, Hart B, et al. Comorbid mental disorders in Fetal Alcohol Spectrum Disorders: A systematic review. J Dev Behav Pediatr. 2017;38(4):283–91. https://doi.org/10.1097/DBP.0000000000000440
7. Pei J, Denys K, Hughes J, et al. Mental health issues in Fetal Alcohol Spectrum Disorder. J Mental Health 2011;20(5):473–83. https://doi.org/10.3109/09638237.2011.577113
8. Streissguth A, Barr H, Kogan J, et al. Understanding the occurence of secondary disabilities in clients with Fetal Alcohol Syndrome (FAS) and Fetal Alcohol Effects (FAE). Seattle, WA:
University of Washington School of Medicine, Dept. of Psychiatry and Behavioral Sciences, Fetal Alcohol and Drug Unit; 1996.
9. Burd L. FASD and ADHD: Are they related and how? BMC Psychiatry 2016;16(1):325. https://doi.org/10.1186/s12888-016-1028-x
10. McLachlan K, Flannigan K, Temple V, et al. Difficulties in daily living experiences by adolescents, transition-aged youth, and adults with Fetal Alcohol Spectrum Disorder. Alcohol Clin Exp Res. 2020;44(8):1609–24. https://doi.org/10.1111/acer.14385
11. O’Connor M, Paley B. Psychiatric conditions associated with prenatal alcohol exposure. Dev Disabil Res Rev. 2009;15(3):225–34. https://doi.org/10.1002/ddrr.74
12. Fryer S, Matt G, Riley E, et al. Evaluation of psychopathological conditions in children with heavy prenatal alcohol exposure. Pediatrics. 2007, Mar;119(3):e733–41. https://doi.org/10.1542/PEDS.2006-1606.
13. Harris SR, Mickelson ECR, Zwicker JG. Diagnosis and management of developmental coordination disorder. Can Med Assoc J. 2015;187(9):659. https://doi.org/10.1503/cmaj.140994
14. American Psychiatric Association (APA). Neurobehavioral disorder associated with prenatal alcohol exposure. In: Diagnostic and statistical manual of mental disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013, pp. 798–801. https://doi.org/10.1176/appi.books.9780890425596
15. Flannigan K, McMorris C, Ewasiuk A, et al. Suicidality and associated factors among individuals assessed for Fetal Alcohol Spectrum Disorder across the lifespan in Canada. Canadian J Psychiatry. 2022;67(5):361–70. https://doi.org/101177/07067437211053288
16. Popova S, Lange S, Bekmuradov D, et al. Fetal Alcohol Spectrum Disorder prevalence estimates in correctional systems: A systematic literature review. Can J Public Health. 2011;102(5):336–40. https://doi.org/10.1007/BF03404172
17. Ji NY, Findling RL. Pharmacotherapy for mental health problems in people with intellectual disability. Curr Opin Psychiatry. 2016;29(2):103–25. https://doi.org/10.1097/YCO.0000000000000233
18. Flannigan K, Coons‐Harding KD, Anderson T, et al. A systematic review of interventions to improve mental health and substance use outcomes for individuals with prenatal alcohol exposure and Fetal Alcohol Spectrum Disorder. Alcohol Clin Exp Res. 2020;44(12):2401–30. https://doi.org/10.1111/acer.14490
19. Petrenko CLM, Alto ME. Interventions in fetal alcohol spectrum disorders: An international perspective. Eur J Med Genet. 2017;60(1):79–91. https://doi.org/10.1016/j.ejmg.2016.10.005
20. Mela M. Prenatal alcohol exposure: A clinician’s guide. Washington, DC: American Psychiatric Publishing (APA); 2021. https://doi.org/10.1176/appi.books.9781615374816
21. Voillemont C, Imbault E, Schoenberger M, et al. Care and management of adults with autism spectrum disorder in family practice: Difficulties experienced by general practitioners. Fam Pract. 2021;39(3):464–70. https://doi.org/10.1093/fampra/cmab126.
22. Branford D, Gerrard D, Saleem N, et al. Stopping over-medication of people with intellectual disability, Autism or both (STOMP) in England, part 1—History and background of STOMP. Adv Ment Heal Intellect Disabil. 2019;13(1):31–40. https://doi.org/10.1108/AMHID-02-2018-0004
23. Halli-Tierney A, Scarbrough C, Carroll D. Polypharmacy: Evaluating risks and deprescribing. Am Fam Physician. 2019;100(1):32–8.
24. Howlett H, Mackenzie S, Strehle E-M, et al. A survey of health care professionals’ knowledge and experience of foetal alcohol spectrum disorder and alcohol use in pregnancy. Clin Med Insights Reprod Health. 2019 Mar 27;13:1179558119838872. https://doi.org/10.1177/1179558119838872
25. O’Malley KD, Koplin B, Dohner VA. Psychostimulant clinical response in fetal alcohol syndrome. Can J Psychiatry. 2000;45(1):90–1.
26. Mela M, Hanlon-Dearman A, Ahmed AG, et al. Treatment algorithm for the use of psychopharmacological agents in individuals prenatally exposed to alcohol and/or with diagnosis of fetal alcohol spectrum disorder (FASD). J Popul Ther Clin Pharmacol. 2020;27(3):e1–13. https://doi.org/10.15586/jptcp.v27i3.681
27. Ozsarfati J, Koren G. Medications used in the treatment of disruptive behavior in children with FASD--A guide. J Popul Ther Clin Pharmacol (J la Ther des Popul la Pharmacol Clin). 2015;22(1):e59–67.
28. Frankel F, Paley B, Marquardt R, et al. Stimulants, neuroleptics, and children’s friendship training for children with fetal alcohol spectrum disorders. J Child Adolesc Psychopharmacol. 2006;16(6):777–89. https://doi.org/10.1089/cap.2006.16.777
29. Coe J, Sidders J, Riley K, et al. A survey of medication responses in children and adolescents with fetal alcohol syndrome. Ment Heal Asp Dev Disabil. 2001;4(4):148–55.
30. Peadon E, Rhys-Jones B, Bower C, et al. Systematic review of interventions for children with Fetal Alcohol Spectrum Disorders. BMC Pediatr. 2009;9(1):35. https://doi.org/10.1186/1471-2431-9-35
31. Mela M, Okpalauwaekwe U, Anderson T, et al. The utility of psychotropic drugs on patients with Fetal Alcohol Spectrum Disorder (FASD): A systematic review. Psychiatry Clin Psychopharmacol. 2018;28(4):436–45. https://doi.org/10.1080/24750573.2018.1458429
32. Ipsiroglu O, Berger M, Lin T, et al. Pathways to overmedication and polypharmacy: Case examples from adolescents with fetal alcohol spectrum disorders. In: Di Pietro N, Illes J, editors. The science and ethics of antipsychotic use in children. Cambridge, MA: Elsevier; 2015, pp. 125–48. https://doi.org/10.1016/B978-0-12-800016-8.00006-4
33. Cook J, Unsworth K, Flannigan K. Characterising Fetal Alcohol Spectrum Disorder in Canada: A national database protocol study. BMJ Open. 2021;11(9):e046071. https://doi.org/10.1136/bmjopen-2020-046071
34. Chudley AE, Conry J, Cook JL, et al. Fetal Alcohol Spectrum Disorder: Canadian guidelines for diagnosis. CMAJ. 2005;172(5 Suppl.):S1–21. https://doi.org/10.1503/cmaj.1040302
35. American Psychiatric Assocation (APA). Diagnostic and statistical manual of mental disorders. Washing, DC: APA; 2013. https://doi.org/10.1176/appi.books.9780890425596
36. Brådvik L. Suicide risk and mental disorders. Int J Environ Res Public Health. 2018 Sep 17;15(9):2028. https://doi.org/10.3390/ijerph15092028.
37. Flannigan K, Wrath AJ, Badry DE, et al. Fetal Alcohol Spectrum Disorder and suicidality: What does the literature tell us? J Mental Health Res Intell Disabilities. 2022;15(3):217–52. https://doi.org/101080/1931586420222082604
38. Greenspan S, Brown NN, Edwards W. FASD and the concept of “intellectual disability equivalence.” In: Nelson M, Trussler M, editors. Fetal alcohol spectrum disorders in adults: Ethical and legal perspectives. International Library of Ethics, Law, and the New Medicine series, 63. Switzerland: Springer; 2016, pp. 63241–66. https://doi.org/10.1007/978-3-319-20866-4_15
39. Temple VK, Cook JL, Unsworth K, et al. Mental health and affect regulation impairment in Fetal Alcohol Spectrum Disorder (FASD): Results from the Canadian National FASD database. Alcohol Alcohol 2019;54(5):545–50. https://doi.org/10.1093/alcalc/agz049
40. Streissguth AP, Bookstein FL, Barr HM, et al. Risk factors for adverse life outcomes in fetal alcohol sydnrome and fetal alcohol effects. J Dev Behav Pediatr. 2004;25(4):228–38. https://doi.org/10.1097/00004703-200408000-00002
41. McLachlan K, McNeil A, Pei J, et al. Prevalence and characteristics of adults with Fetal Alcohol Spectrum Disorder in corrections: A Canadian case ascertainment study. BMC Public Health. 2019 Jan 9;19(1):43. https://doi.org/10.1186/s12889-018-6292-x.
42. Mawani F, Gilmour H. Validation of self-rated mental health. Stat Canada Heal Rep. 2010;21(3):1–15.
43. Fleishman J, Zuvekas S. Global self-rated mental health: Associations with other mental health measures and with role functioning. Med Care. 2007;45(7):602–9. https://doi.org/10.1097/MLR.0b013e31803bb4b
44. Flannigan K, McLachlan K, Pei J, et al. Fetal Alcohol Spectrum Disorder and adversity. Vancouver, BC: Canada Fetal Alcogol Spectrum Disorder Research Network; 2020, 6 p.
45. Mela M, Coons-Harding KD, Anderson T. Recent advances in Fetal Alcohol Spectrum Disorder for mental health professionals. Curr Opin Psychiatry. 2019;32(4):328–35. https://doi.org/10.1097/YCO.0000000000000514
46. American Psychiatric Association (APA). Bipolar and related disorders. In: Diagnostic and statistical manual of mental disorders-5. Washington, DC: American Psychiatric Association; 2013, pp. 123–39. https://doi.org/10.1176/appi.books.9780890425596
47. Government of Canada. Suicide in Canada: Key statistics [Internet]. [cited 2020]. Available at: https://www.canada.ca/en/public-health/services/publications/healthy-living/suicide-canada-key-statistics-infographic.html. Accessed November 22, 2021.
48. Van Ameringen M, Mancini C, Patterson B, et al. Post-traumatic stress disorder in Canada. CNS Neurosci Ther. 2008;14(3):171–81. https://doi.org/10.1111/j.1755-5949.2008.00049.x.
49. Dobson KG, Vigod SN, Mustard C, et al. Trends in the prevalence of depression and anxiety disorders among Canadian working-age adults between 2000 and 2016. Ottawa, ON: NLM (Medline); 2020 Dec 16, pp. 12–23. Epub ahead of print. https://doi.org/10.25318/82-003-X202001200002-ENG.
50. Fast DK, Conry J. Understanding the similarities and differences between Fetal Alcohol Spectrum Disorder and mental health disorders [Internet]. [cited 2017]. Ottawa, ON: Research and Statistics Division Department of Justice Canada. Available at: https://www.justice.gc.ca/eng/rp-pr/csj-sjc/esc-cde/rr13_10/p2.html.
51. Ivanović I. Psychiatric comorbidities in children with ASD: Autism centre experience. Front Psychiatry. 2021 Jun 9;12:673169. https://doi.org/10.3389/FPSYT.2021.673169.
52. Mela M, McFarlane A, Sajobi TT, et al. Clinical correlates of fetal alcohol spectrum disorder among diagnosed individuals in a rural diagnostic clinic . J Popul Ther Clin Pharmacol. 2013;20(3):e250–8.
53. Novick Brown N, Connor PD, Adler RS. Conduct-disordered adolescents with fetal alcohol spectrum disorder. Crim Justice Behav. 2012;39(6):770–93. https://doi.org/10.1177/0093854812437919
54. Frankel F, Paley B, Marquardt R, et al. Stimulants, neuroleptics, and children’s friendship training for children with Fetal Alcohol Spectrum Disorders. J Child Adolesc Psychopharmacol. 2006;16(6):777–89. https://doi.org/10.1089/cap.2006.16.777
55. Lillig M. Diagnostic criteria for conduct disorder. In: Diagnostic and statistical manual of mental disorders,4th ed, text revision (DSM-IV-TR). Arlington, VA: American Psychiatric Association; 2007, p. 85-91. https://doi.org/10.1176/appi.books.9780890423349.7856.
56. Komossa K, Depping A, Meyer M, et al. Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst Rev. 2010;12:1–50. https://doi.org/10.1002/14651858.CD008141.pub2
57. Sansone RA, Sansone LA. Managing bipolar disorder in the primary care setting: A perspective for mental health professionals. Innov Clin Neurosci. 2011;8(10):10–3.
58. Fremont WP, Nastasi R, Newman N, et al. Comfort level of pediatricians and family medicine physicians diagnosing and treating child and adolescent psychiatric disorders. Int J Psychiatry Med. 2008;38(2):153–68. https://doi.org/10.2190/PM.38.2.c
59. Baldwin D, Anderson I, Nutt D, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403–39. https://doi.org/10.1177/0269881114525674
60. Rowles BM, Findling RL. Review of pharmacotherapy options for the treatment of attention-deficit/hyperactivity disorder (ADHD) and ADHD-like symptoms in children and adolescents with developmental disorders. Dev Disabil Res Rev. 2010;16(3):273–82. https://doi.org/10.1002/ddrr.120
61. Oesterheld JR, Kofoed L, Tervo R, et al. Effectiveness of methylphenidate in native American children with fetal alcohol syndrome and attention deficit/hyperactivity disorder: A controlled pilot study. J Child Adolesc Psychopharmacol. 1998;8(1):39–48. https://doi.org/10.1089/cap.1998.8.39
62. Snyder J, Nanson J, Snyder R, et al. A study of stimulant medication in children with FAS. In: Streissguth AP, Kanter J, editors. The challenge of fetal alcohol syndrome: Overcoming secondary disabilities. Seattle, WA: University of Washington Press; 1997, p. 64-77
63. Franke B, Michelini G, Asherson P, et al. Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. Eur Neuropsychopharmacol. 2018;28(10):1088. https://doi.org/10.1016/j.euroneuro.2018.08.001
64. Caye A, Swanson JM, Coghill D, et al. Treatment strategies for ADHD: An evidence-based guide to select optimal treatment. Mol Psychiatry. 2018;24(3):390–408. https://doi.org/10.1038/s41380-018-0116-3
65. Persico A, Ricciardello A, Lamberti M, et al. The pediatric psychopharmacology of autism spectrum disorder: A systematic review—Part I: The past and the present. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Aug 30;110:110326. https://doi.org/10.1016/J.PNPBP.2021.110326.
66. Schubiner H, Tzelepis A, Milberger S, et al. Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. J Clin Psychiatry. 2000;61(4):244–51. https://doi.org/10.4088/JCP.v61n0402
67. Hanlon-Dearman A, Chen ML, Olson HC. Understanding and managing sleep disruption in children with Fetal Alcohol Spectrum Disorder 1. Biochem Cell Biol. 2018;96(2):267–74. https://doi.org/10.1139/bcb-2017-0064
68. Alvaro P, Roberts R, Harris J. A systematic review assessing bidirectionality between sleep disturbances, anxiety, and depression. Sleep. 2013;36(7):1059–68. https://doi.org/10.5665/sleep.2810
69. Feriante J, Bernstein B. Separation anxiety. In: StatPearls [Internet]. [cited 2021]. Treasure Island, FL: StatPearls; phttps://pubmed.ncbi.nlm.nih.gov/32809628/ Accessed July 26, 2021.
70. Ricketts E, Burgess H, Montalbano G, et al. Morning light therapy in adults with Tourette’s disorder. J Neurol. 2022;269(1):399–410. https://doi.org/10.1007/S00415-021-10645-Z.
71. Konofal E, Lecendreux M, Cortese S. Sleep and ADHD. Sleep Med. 2010;11(7):652–8. https://doi.org/10.1016/j.sleep.2010.02.012